Russell Alan J sold $7.9M of EWTX
Russell Alan J (Chief Scientific Officer) sold 200,000 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $39.41 ($39.41–$39.41, $7.88M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete, time-stamped insider selling event (200,000 shares, ~$7.88M) but does not include new operational, clinical, or financial information.
Market read
Traders may use the filing to gauge insider activity and sentiment, but it is unlikely to drive a fundamental repricing on its own.
What to watch
Insider sales can be misread without context on prior 10b5-1 schedules, total insider ownership changes, and whether other insiders filed concurrent transactions.
Background
The article summarizes an SEC Form 4 insider transaction by Edgewise Therapeutics CSO Russell Alan J.
Ticker impact
Edgewise Therapeutics CSO Russell Alan J sold about 200,000 shares in open-market transactions totaling $7.88M under a 10b5-1 plan.
Likely limited, short-lived sentiment impact; watch for follow-on selling signals in subsequent filings.
The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- issuerEdgewise Therapeutics, Inc.
Company whose CSO executed open-market sales under a 10b5-1 plan.
- insiderRussell Alan J
Chief Scientific Officer and director who sold shares.
